TxCell SA, a biopharma company developing personalized cellular immunotherapies using regulatory T-cells to treat inflammatory and autoimmune diseases, has selected PCT as its contract manufacturing organization in the U.S. The relationship may transition to a technology transfer, with PCT having responsibility for the future manufacturing of TxCell’s clinical supply in the U.S.   PCT, a subsidiary of Caladrius Biosciences, is a development and manufacturing partner for cell therapies. PCT hel...